10-K: Agilon Health Reports 2023 Results: Revenue Surges 81% Amidst Net Losses

Agilon Health's 2023 annual report reveals an 81% revenue increase driven by membership growth, alongside a net loss of $262.8 million.

Summary

• Agilon Health's 2023 financial results show a significant increase in revenue, reaching $4.32 billion, an 81% jump compared to the previous year.
• The company's total membership grew substantially, with Medicare Advantage members increasing by 68% to approximately 388,400.
• However, the company experienced a net loss of $262.8 million, a considerable increase from the $106.9 million loss in 2022.
• The medical margin was $298.7 million, slightly up from $291.0 million in the prior year.
• Adjusted EBITDA showed a loss of $95.0 million, compared to a loss of $45.5 million in 2022.
• The company's platform support costs were $163.7 million, representing 4% of revenue.
• The company also completed the disposition of its Hawaii operations during the year.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue growth is strong, the significant increase in net losses and the identified material weakness in internal controls raise concerns. The need for potential future capital raises also adds to the uncertainty. Overall, the sentiment is cautiously negative.

Positives

• The company experienced substantial revenue growth of 81% year-over-year.
• Medicare Advantage membership increased significantly by 68%.

Negatives

• The company's net loss increased substantially to $262.8 million.
• Adjusted EBITDA showed a loss of $95.0 million, a significant increase from the previous year's loss.
• Gross profit decreased from $111.4 million to $69.7 million.

Risks

• The company has a history of net losses and expects expenses to increase in the future.
• There is a risk of failure to identify and develop successful new geographies, physician partners, and payors.
• Medical expenses incurred on behalf of members may exceed revenues received.
• The company faces competition in the healthcare industry.
• There are risks associated with government healthcare program changes and regulations.
• The company relies on third-party software, data, infrastructure and bandwidth.
• The company has identified a material weakness in its internal control over financial reporting.

Future Outlook

The company expects to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to investments in expanding the business and additional general and administrative costs related to operating as a public company. The company believes that its existing cash and cash equivalents, as well as available borrowing capacity under the Credit Facility, will be sufficient to meet its working capital and capital expenditure needs over at least the next 12 months.

Management Comments

• The company believes that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost and patient experience when provided with the right infrastructure and payment model.
• The company's model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners attributed patients (or global capitation arrangements).

Industry Context

The healthcare industry is highly competitive and fragmented, with increasing consolidation among providers and payors. Agilon Health competes with other value-based care providers, local provider networks, hospitals, and health systems. Large payors are also developing their own managed care services, increasing competition.

Comparison to Industry Standards

• Agilon Health's model is differentiated by its focus on existing community-based physician groups, which is a unique approach compared to some competitors.
• While some competitors utilize elements of the MA multi-payor, globally capitated risk model, Agilon believes none offer a model that captures all elements of the agilon model.
• Competitors typically vary by geography, and Agilon may encounter competition from new entrants in the future.
• The company's growth strategy could be adversely affected if it cannot access existing geographies, expand into new ones, or maintain relationships with payors and physician partners.

Related Party Transactions

• The company has a consulting agreement with CD&R, for which it paid advisory consulting fees.
• The company has a stockholders agreement with CD&R Vector Holdings, L.P.
• The company has a registration rights agreement with CD&R Vector Holdings, L.P.

Stakeholder Impact

• Shareholders may be concerned about the increased net losses and the material weakness in internal controls.
• Employees may be affected by potential changes in operations and the need for improved internal controls.
• Physician partners may be impacted by the company's ability to manage medical costs and provide support.
• Payors may be concerned about the company's financial stability and ability to manage risk.

Next Steps

• The company will continue to improve its existing systems for operational and financial management.
• The company will continue to implement its growth strategy by expanding into new geographies and partnering with new physician groups.
• The company will continue to monitor the effectiveness of its remediation measures for the identified material weakness.

Key Dates

Keywords

Medicare Advantage, value-based care, capitation, physician partners, healthcare, risk-bearing, ACO REACH, membership growth, financial results, revenue